BOSTON--(BUSINESS WIRE)--Allotex Inc., a commercial-stage ophthalmic company with active European market adoption, today announced that the U.S. Food and Drug Administration (FDA) has conditionally ...
BOSTON--(BUSINESS WIRE)--Allotex, a Boston based private company developing the TransForm Corneal Allograft (TCA) for the treatment of presbyopia (reading glasses) and hyperopia (far sightedness), is ...
Allotex is advancing a natural, biologic approach to vision correction announced global commercial rollout under the new leadership of Michael Mrochen. BOSTON, MA, UNITED STATES, May 1, 2025 ...
BOSTON and MILAN, Nov. 30, 2023 /PRNewswire/ -- Allotex Inc. and SpA, a leading biologics and device company specializing in vision correction therapies, is pleased to announce that Junson Capital has ...
Allotex and 3D-Micromac recently announced a cooperative agreement to develop and market a laser system for shaping corneal grafts manufactured from human donor corneas, offering clinicians and ...
MILANO, ITALY, June 3, 2025 /EINPresswire.com/ -- Allotex group, a leader in natural tissue-based vision correction solutions, today announced the appointment of Dirk ...
BOSTON and MILAN, Dec. 1, 2023 /PRNewswire/ -- Allotex Inc. and SpA, a leading biologics and device company specializing in vision correction therapies, is pleased to announce that Junson Capital has ...
Allotex, a Boston based private company developing the TransForm Corneal Allograft (TCA) for the treatment of presbyopia (reading glasses) and hyperopia (far sightedness), is pleased to report that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results